The stock of OvaScience Inc (NASDAQ:OVAS) reached all time low today, Nov, 4 and still has $3.45 target or 13.00% below today’s $3.96 share price. This indicates more downside for the $139.70M company. This technical setup was reported by Barchart.com. If the $3.45 PT is reached, the company will be worth $18.16M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 670,486 shares traded hands or 71.22% up from the average. OvaScience Inc (NASDAQ:OVAS) has declined 50.74% since April 4, 2016 and is downtrending. It has underperformed by 51.83% the S&P500.
OvaScience Inc (NASDAQ:OVAS) Ratings Coverage
Out of 5 analysts covering OvaScience (NASDAQ:OVAS), 1 rate it a “Buy”, 1 “Sell”, while 3 “Hold”. This means 20% are positive. OvaScience has been the topic of 9 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The stock of OvaScience Inc (NASDAQ:OVAS) earned “Outperform” rating by Oppenheimer on Wednesday, October 21. The firm has “Mkt Perform” rating given on Tuesday, September 29 by JMP Securities. Credit Suisse initiated OvaScience Inc (NASDAQ:OVAS) on Thursday, January 21 with “Underperform” rating. As per Wednesday, September 30, the company rating was maintained by Oppenheimer. Leerink Swann downgraded the shares of OVAS in a report on Monday, November 9 to “Market Perform” rating. Leerink Swann maintained it with “Outperform” rating and $48 target price in Friday, August 14 report. Wedbush maintained OvaScience Inc (NASDAQ:OVAS) rating on Tuesday, August 11. Wedbush has “Outperform” rating and $46 price target. The stock of OvaScience Inc (NASDAQ:OVAS) earned “Perform” rating by Oppenheimer on Monday, January 25.
According to Zacks Investment Research, “OvaScience, Inc. is a life science company focused on the discovery, development and commercialization of new treatments for infertility. Its product includes Augment for the treatment of infertility and Ova Ture used in the creation of mature fertilizable eggs. Ova Science, Inc. is headquartered in Cambridge, Massachusetts.”
Insitutional Activity: The institutional sentiment increased to 3.37 in 2016 Q2. Its up 2.50, from 0.87 in 2016Q1. The ratio is positive, as 7 funds sold all OvaScience Inc shares owned while 12 reduced positions. 17 funds bought stakes while 47 increased positions. They now own 51.93 million shares or 132.78% more from 22.31 million shares in 2016Q1.
Northern Tru holds 0% or 236,783 shares in its portfolio. Zurcher Kantonalbank (Zurich Cantonalbank), a Switzerland-based fund reported 359 shares. Retail Bank Of America De last reported 0% of its portfolio in the stock. Gmt Cap Corp has invested 0.06% of its portfolio in OvaScience Inc (NASDAQ:OVAS). Proshare Advsr Ltd Liability Company last reported 0% of its portfolio in the stock. Bnp Paribas Arbitrage Sa last reported 0% of its portfolio in the stock. Amici Cap Ltd holds 0.01% of its portfolio in OvaScience Inc (NASDAQ:OVAS) for 10,000 shares. Numeric Investors Lc has invested 0% of its portfolio in OvaScience Inc (NASDAQ:OVAS). Goldman Sachs Gru holds 12,246 shares or 0% of its portfolio. Fmr Limited Liability Company accumulated 0% or 5.17 million shares. Moreover, Diam has 0.03% invested in OvaScience Inc (NASDAQ:OVAS) for 339,626 shares. Brandywine Global Invest Mgmt Lc, a Pennsylvania-based fund reported 8,600 shares. Swiss National Bank, a Switzerland-based fund reported 44,550 shares. Jennison Associates Ltd Com owns 3.09 million shares or 0.02% of their US portfolio. Blackrock Institutional Tru Co Na accumulated 0% or 634,300 shares.
Insider Transactions: Since May 10, 2016, the stock had 10 buys, and 0 sales for $1.76 million net activity. On Thursday, May 12 the insider Dipp Michelle bought $250,395. Another trade for 20,000 shares valued at $157,200 was bought by ALDRICH RICHARD. CHAPMAN PAUL W.D. bought $22,847 worth of OvaScience Inc (NASDAQ:OVAS) on Tuesday, May 10.
OVAS Company Profile
OvaScience, Inc., incorporated on April 5, 2011, is a global fertility company. The Firm is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue. The Company’s AUGMENT treatment is specifically designed to improve egg health by supplementing a mitochondrial deficiency. With the AUGMENT treatment, energy-producing mitochondria from a patient’s own EggPC cells are added to the patient’s mature eggs during the in vitro fertilization (IVF) process to supplement the existing mitochondria.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.